Director Fred Hassan filed a Form 4 with the SEC on November 4, 2026, disclosing the acquisition of 156,658 restricted stock units in Recursion Pharmaceuticals, Inc. on November 2, 2026.

Key Highlights

  • Reporting person: Fred Hassan, identified as a Director of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX).
  • Grant size: 156,658 restricted stock units (RSUs) of Class A Common Stock were acquired on November 2, 2026.
  • Price paid: $0, reflecting an automatic grant at no cost to the director.
  • Vesting schedule: The RSUs vest in equal thirds on each of the first three anniversaries of November 2, 2026, subject to continued service.
  • Policy basis: The grant was made automatically pursuant to Recursion's Outside Director Compensation Policy.
  • Resulting ownership: Following the transaction, Hassan directly and beneficially owns 156,658 shares of Class A Common Stock.

RSU Award to Director Hassan Under Outside Director Compensation Policy

According to the filing, Fred Hassan, a Director at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), received an automatic grant of 156,658 restricted stock units on November 2, 2026. The filing identifies the transaction code as "A" (acquired) and states the price as $0, consistent with a director compensation award rather than an open-market purchase.

The filing's footnote explains that the grant was made "automatically granted pursuant to Recursion's Outside Director Compensation Policy." The RSUs are structured to vest as to "1/3rd of the shares subject to the award on the first three anniversaries of November 2, 2026," contingent on Hassan continuing to be a service provider through each applicable vesting date. No derivative securities were reported in Table II of the filing.

The Form 4 was signed by Kyle Nelson as attorney-in-fact on November 2, 2026, and filed with the SEC on November 4, 2026. Following the reported transaction, Hassan's direct beneficial ownership in Class A Common Stock stands at 156,658 shares, as reported in the filing.

What Was Disclosed

This Form 4 discloses an automatic RSU grant of 156,658 Class A Common Stock units to Director Fred Hassan at $0 cost, made on November 2, 2026, under Recursion Pharmaceuticals' Outside Director Compensation Policy, with a three-year annual vesting schedule.